Rivastigmine Synthesis via Chiral Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Rivastigmine or its pharmaceutically acceptable salts are economically unviable due to the use of expensive chiral catalysts and corrosive reagents, leading to low yields and optical impurities, making large-scale industrial production challenging.
Innovation Solution
A process involving the reaction of a compound with phthalic anhydride, followed by a chiral resolving agent, and subsequent conversion steps to obtain Rivastigmine, which reduces the need for expensive chiral catalysts and avoids corrosive reagents, enhancing yield and optical purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral coordinated transition metal complexes are used for stereo-selective reduction, then the desired (S)-isomer is formed with high optical purity, but the process becomes expensive and uneconomical for industrial scale
Solution Approach 1:
The patent replaces expensive chiral coordinated transition metal complexes with inexpensive chiral resolving agents such as (R)-1-phenylethylamine. The resolving agent forms diastereomeric salts with the racemic amine intermediate, allowing separation of enantiomers through simple filtration and crystallization, eliminating the need for costly metal catalysts while maintaining high optical purity
Solution Approach 2:
The patent introduces chiral resolving agents as intermediaries that temporarily bind to the racemic amine to form diastereomeric complexes. These intermediaries enable enantiomeric separation through differential solubility and crystallization behavior, serving as a bridge between the racemic mixture and the optically pure product without requiring expensive catalytic systems
2Manufacturing precision
If enzymatic reduction or resolution processes are used, then enantiomerically enriched product is obtained, but the reaction cycle becomes longer and requires special techniques for enzyme screening
Solution Approach 1:
The patent replaces complex enzymatic systems with simple chemical resolving agents. The chemical resolution process using (R)-1-phenylethylamine proceeds rapidly under conventional conditions without requiring enzyme screening, optimization, or specialized biocatalytic techniques, significantly reducing process time while achieving the same enantiomeric enrichment
3Manufacturing precision
If conventional resolution of racemic amine is performed, then optically active compound is obtained, but yield is low and repeated crystallization is required
Solution Approach 1:
The patent performs preliminary protection of the phenolic hydroxyl group as a methyl ether before the resolution step. This preliminary action prevents side reactions and simplifies the resolution process, allowing high-yield formation of the desired enantiomer in a single crystallization step rather than requiring repeated cycles to achieve sufficient purity
4Ease of manufacture
If processes involving corrosive reagents like phosphorus tribromide are used, then Rivastigmine is prepared, but environmental impact increases and process viability decreases
Solution Approach 1:
The patent replaces corrosive reagents like phosphorus tribromide with mild, environmentally benign alternatives. The methodology uses standard protecting group chemistry and conventional resolution techniques that avoid hazardous substances, making the process both economically viable and environmentally sustainable for industrial application
Data Source
AI summary
The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).